/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Stantec announces first quarter 2019 results
![](https://i0.wp.com/picante.today/wp-content/uploads/2019/05/7798_square.jpg?fit=150%2C150&ssl=1)
EDMONTON, Alberta & NEW YORK–(BUSINESS WIRE)–Stantec today announced its financial results for the quarter ended
March 31, 2019. “Our solid first-quarter performance reflects our
continued focus on organic and acquisition growth,” said Stantec
president and chief executive officer Gord Johnston. “We are
particularly pleased with the strong organic growth achieved in our
global business, which demonstrates the value of our growing geographic
reach and augments the diversity of our business mix.”
Effective January 1, 2019, Stantec adopted IFRS 16 Leases using
the modified retrospective approach and did not restate comparative
information.
Q1 2019 Highlights
After adoption of IFRS 16
-
Adjusted net income of $50.3 million or $0.45 on a diluted per share
basis, increases of 5.0% and 7.1%, respectively, compared to Q1 18. -
Net income of $44.9 million or $0.40 on a diluted per share basis,
increases of 22.0% and 25.0%. -
Gross and net revenue of $1,151.5 million and $904.1 million,
respectively, reflecting growth of 12.7% and 11.8%, with increases
across all geographies. -
Organic net revenue growth of 2.5%, with growth in all geographies and
business operating units, except Water, where growth was offset by the
effect of a large recovery recognized in Q1 18. -
Acquisition net revenue growth of 6.6% compared to Q1 18,
predominately from the recent global acquisitions of Peter Brett
Associates and Wood & Grieve Engineers (WGE). - Adjusted EBITDA of $127.1 million, representing 14.1% of net revenue.
- EBITDA of $132.2 million, representing 14.6% of net revenue.
-
Contract backlog of $4.4 billion—a 5.6% increase from December 31,
2018—representing 12 months of work. -
Days sales outstanding (DSO) of 104 days (90 days including deferred
revenue), an increase of one day from December 31, 2018. Reducing DSO
continues to be a key focus for the Company. -
Net debt to adjusted EBITDA of 2.0x—at the upper end of the Company’s
internal guideline of 1.0x to 2.0x (post-IFRS 16 adoption) due to
typically lower cash flows in Q1, funding the WGE acquisition,
opportunistic share repurchases, and the impact of only one month’s
EBITDA contribution from WGE. -
On May 9, 2019, the Board of Directors declared a dividend of $0.145
per share, payable on July 15, 2019, to shareholders on record on June
28, 2019.
Excluding adoption of IFRS 16:
-
Adjusted net income and diluted earnings per share (EPS)—no
significant impact. - Net income and diluted EPS—no significant impact.
-
Adjusted EBITDA of $91.6 million—a 2.3% increase from Q1 18,
representing 10.1% of net revenue. -
EBITDA of $96.7 million—an 11.3% increase from Q1 18, representing
10.7% of net revenue. - Net debt to adjusted EBITDA of 2.67x.
Financial Summary
Quarter Ended March 31 | |||||||
(In millions of Canadian dollars, except per share amounts) |
2019
$ |
2018
$ |
Change $ |
||||
Gross revenue | 1,151.5 | 1,021.3 | 130.2 | ||||
Net revenue | 904.1 | 808.8 | 95.3 | ||||
EBITDA from continuing operations (1) | 132.2 | 86.9 | 45.3 | ||||
– Excluding IFRS 16 (1) | 96.7 | 86.9 | 9.8 | ||||
Net income from continuing operations | 44.9 | 36.6 | 8.3 | ||||
Net income from discontinued operations | – | 0.2 | (0.2) | ||||
Net income | 44.9 | 36.8 | 8.1 | ||||
Basic and diluted earnings per share (EPS) from continuing operations |
0.40 | 0.32 | 0.08 | ||||
Dividends declared per common share | 0.1450 | 0.1375 | 0.0075 | ||||
Continuing operations | |||||||
Adjusted EBITDA (1) | 127.1 | 89.5 | 37.6 | ||||
– Excluding IFRS 16 (1) | 91.6 | 89.5 | 2.1 | ||||
Adjusted net income (1) | 50.3 | 47.9 | 2.4 | ||||
Adjusted EPS – basic and diluted (1) | 0.45 | 0.42 | 0.03 | ||||
(1) EBITDA, adjusted EBITDA, adjusted net income, and adjusted basic and diluted EPS are non-IFRS measures (discussed in the Definitions section of Stantec’s 2018 Annual Report and Q1 19 Management’s Discussion and Analysis). |
Revised Annual Targets for 2019
The Company expects IFRS 16
will reduce 2019 net income by approximately $3.0 million and EPS by
$0.03 evenly over Q2 19 to Q4 19. Adoption of IFRS 16 resulted in
non-cash impacts to administrative and marketing expenses, depreciation
of leased assets, and net interest expense. As a result, the Company
updated its targets, previously provided in its 2018 Annual Report. The
Company revised its EBITDA and net income targets to adjusted EBITDA and
adjusted net income since it believes these measures better reflect its
underlying operations.
Measure |
Previously Published |
Revised 2019 Annual
|
Q1 19 Results
|
||||
Gross margin as % of net revenue | 53% to 55% | No change | 54.0% | ||||
Administrative and marketing expenses as % of net revenue | 41% to 43% | 37% to 39% | 39.5% | ||||
EBITDA as % of net revenue (note) | 11% to 13% | withdrawn | |||||
Adjusted EBITDA as % of net revenue (note) | 15% to 17% | 14.1% | |||||
Net income as % of net revenue | At or above 5.0% | withdrawn | |||||
Adjusted net income as % of net revenue (note) | At or above 6.0% | 5.6% | |||||
A complete list of 2019 targets is presented in the Financial Targets section of Stantec’s Q1 2019 Management’s Discussion and Analysis and in the Investors section of stantec.com. |
|||||||
(1) EBITDA, adjusted EBITDA, and adjusted net income, are non-IFRS measures (discussed in the Definitions section of Stantec’s 2018 Annual Report and Q1 19 Management’s Discussion and Analysis). |
|||||||
* 2019 Target Range was previously published in Stantec’s 2018 Annual Report. |
Q1 19 results are consistent with the Company’s expectations. Certain
measures are outside the targeted annual ranges due to the typical
slowdown in the first quarter related to winter weather conditions and
holiday schedules. This also occurs in the fourth quarter. The Company
is confident it will achieve its annual targets by the end of the fiscal
year.
Conference Call and Annual General Meeting of Shareholders
On Friday, May 10, 2019, at 7:00 AM MDT (9:00 AM EDT), Stantec’s first
quarter 2019 conference call and slideshow presentation will be
broadcast live and archived in their entirety in the Investors
section of stantec.com.
Those wishing to listen to the call can phone toll-free at
1-888-220-8451 (Canada and United States) or 1-647-484-0475
(international). Please provide confirmation code 3085729 when prompted.
Stantec’s Annual General Meeting of Shareholders will be held on Friday,
May 10, 2019, at 10:30 AM MDT (12:30 PM EDT) at Stantec Tower, 400-10220
103 Avenue NW, Edmonton, Alberta, Canada.
Investor Day
Stantec’s Investor Day will be held on Wednesday, June 12, 2019, at the
Stantec Tower in Edmonton, Alberta. Gord Johnston, CEO, and Theresa
Jang, CFO, will share details on the Company’s strategy and outlook.
Leaders of the Company’s business and regional operating units will
provide additional insight into Stantec’s growth opportunities.
About Stantec
Communities are fundamental. Whether around the corner or across the
globe, they provide a foundation, a sense of place and of belonging.
That’s why at Stantec, we always design with community in mind.
We care about the communities we serve—because they’re our
communities too. This allows us to assess what’s needed and connect our
expertise, to appreciate nuances and envision what’s never been
considered, to bring together diverse perspectives so we can collaborate
toward a shared success.
We’re designers, engineers, scientists, and project managers,
innovating together at the intersection of community, creativity, and
client relationships. Balancing these priorities results in projects
that advance the quality of life in communities across the globe.
Stantec trades on the TSX and the NYSE under the symbol STN. Visit us
at stantec.com or find us on social media.
Cautionary Statements
Stantec’s EBITDA, adjusted EBITDA, adjusted net income, adjusted
basic and diluted earnings per share, and days sales outstanding are
non-IFRS measures. For a definition and explanation of non-IFRS
measures, refer to the Critical Accounting Estimates, Developments, and
Measures section of the Company’s 2018 Annual Report or the Q1 2019
Management’s Discussion & Analysis.
Certain statements contained in this news release constitute
forward-looking statements. Forward-looking statements in this news
release include, but are not limited to, statements relating to the
Company’s focus on reducing DSO, and updated guidance relating to
Stantec’s 2019 financial targets. Any such statements represent the
views of management only as of the date hereof and are presented for the
purpose of assisting the Company’s shareholders in understanding
Stantec’s operations, objectives, priorities, and anticipated financial
performance as at and for the periods ended on the dates presented and
may not be appropriate for other purposes. By their nature,
forward-looking statements require us to make assumptions and are
subject to inherent risks and uncertainties.
We caution readers of this news release not to place undue reliance
on our forward-looking statements since a number of factors could cause
actual future results to differ materially from the expectations
expressed in these forward-looking statements. These factors include,
but are not limited to, the risk of economic downturn, decreased
infrastructure spending levels, changing market conditions for Stantec’s
services, and the risk that Stantec fails to capitalize on its strategic
initiatives. Investors and the public should carefully consider these
factors, other uncertainties, and potential events, as well as the
inherent uncertainty of forward-looking statements, when relying on
these statements to make decisions with respect to our Company.
For more information about how other material risk factors could
affect our results, refer to the Risk Factors section and Cautionary
Note Regarding Forward-Looking Statements section in our 2018 Annual
Report. You may access our annual report online by visiting EDGAR on the
SEC website at sec.gov
or by visiting the CSA website at sedar.com
or Stantec’s website, stantec.com.
You may obtain a hard copy of the 2018 Annual Report free of charge from
our investor contact noted below.
Design with community in mind
Attached to this news release are Stantec’s consolidated statements
of financial position, consolidated statements of income, a summary of
impacts of IFRS 16, and reconciliation of non-IFRS measures.
Consolidated Statements of Financial Position
(Unaudited) | |||||
(In millions of Canadian dollars) |
March 31 $ |
December 31 $ |
|||
ASSETS | |||||
Current | |||||
Cash and deposits | 96.9 | 185.2 | |||
Trade and other receivables | 825.0 | 878.1 | |||
Unbilled receivables | 450.3 | 384.6 | |||
Contract assets | 61.7 | 59.7 | |||
Income taxes recoverable | 68.0 | 47.9 | |||
Prepaid expenses | 53.0 | 56.8 | |||
Other assets | 27.6 | 23.2 | |||
Total current assets | 1,582.5 | 1,635.5 | |||
Non-current | |||||
Property and equipment | 299.5 | 289.4 | |||
Lease assets | 551.7 | – | |||
Goodwill | 1,688.8 | 1,621.2 | |||
Intangible assets | 276.0 | 247.7 | |||
Investments in joint ventures and associates | 9.1 | 9.4 | |||
Net employee defined benefit asset | 11.9 | 10.0 | |||
Deferred tax assets | 23.9 | 21.2 | |||
Other assets | 183.0 | 175.5 | |||
Total assets | 4,626.4 | 4,009.9 | |||
LIABILITIES AND EQUITY | |||||
Current | |||||
Bank indebtedness | 43.1 | – | |||
Trade and other payables | 468.4 | 567.2 | |||
Lease liabilities | 38.5 | – | |||
Deferred revenue | 172.9 | 174.4 | |||
Income taxes payable | 1.2 | 2.9 | |||
Long-term debt | 64.6 | 48.5 | |||
Provisions | 36.0 | 42.4 | |||
Other liabilities | 6.5 | 23.2 | |||
Total current liabilities | 831.2 | 858.6 | |||
Non-current | |||||
Lease liabilities | 602.8 | – | |||
Income taxes payable | 17.3 | 15.9 | |||
Long-term debt | 1,042.0 | 885.2 | |||
Provisions | 84.4 | 78.2 | |||
Net employee defined benefit liability | 59.8 | 68.6 | |||
Deferred tax liabilities | 77.1 | 54.3 | |||
Other liabilities | 49.0 | 140.4 | |||
Total liabilities | 2,763.6 | 2,101.2 | |||
Shareholders’ equity | |||||
Share capital | 868.6 | 867.8 | |||
Contributed surplus | 25.4 | 24.8 | |||
Retained earnings | 837.1 | 851.2 | |||
Accumulated other comprehensive income | 130.0 | 163.1 | |||
Total shareholders’ equity | 1,861.1 | 1,906.9 | |||
Non-controlling interests | 1.7 | 1.8 | |||
Total liabilities and equity | 4,626.4 | 4,009.9 |
Consolidated Statements of Income
(Unaudited) | |||||
For the quarter ended March 31 |
|||||
(In millions of Canadian dollars, except per share amounts) |
2019
$ |
2018 $ |
|||
Continuing operations | |||||
Gross revenue | 1,151.5 | 1,021.3 | |||
Less subconsultant and other direct expenses | 247.4 | 212.5 | |||
Net revenue | 904.1 | 808.8 | |||
Direct payroll costs | 415.6 | 368.3 | |||
Gross margin | 488.5 | 440.5 | |||
Administrative and marketing expenses | 357.1 | 348.0 | |||
Depreciation of property and equipment | 13.7 | 12.1 | |||
Depreciation of lease assets | 27.4 | – | |||
Amortization of intangible assets | 15.4 | 19.3 | |||
Net interest expense | 17.2 | 5.3 | |||
Other net finance expense | 1.3 | 1.6 | |||
Share of income from joint ventures and associates | – | (0.3) | |||
Foreign exchange loss | 2.9 | 2.1 | |||
Other (income) expense | (5.0) | 2.2 | |||
Income before income taxes and discontinued operations | 58.5 | 50.2 | |||
Income taxes | |||||
Current | (4.2) | 13.7 | |||
Deferred | 17.8 | (0.1) | |||
Total income taxes | 13.6 | 13.6 | |||
Net income for the period from continuing operations | 44.9 | 36.6 | |||
Discontinued operations | |||||
Net income from discontinued operations, net of tax | – | 0.2 | |||
Net income for the period | 44.9 | 36.8 | |||
Weighted average number of shares outstanding – basic | 111,805,946 | 114,064,729 | |||
Weighted average number of shares outstanding – diluted | 111,805,946 | 114,306,834 | |||
Shares outstanding, end of the period | 111,657,956 | 113,906,006 | |||
Earnings per share, basic and diluted | |||||
Continuing operations | 0.40 | 0.32 | |||
Discontinued operations | – | – | |||
Total basic and diluted earnings per share | 0.40 | 0.32 |
Impact on Statement of Financial Position at January 1, 2019 | |||||||
(In millions of Canadian dollars) |
IFRS 16
$ |
Before IFRS 16
$ |
Increase
(decrease) $ |
||||
Current assets | |||||||
Trade and other receivables | 828.1 | 878.1 | (50.0) | ||||
Prepaid expenses | 43.9 | 56.8 | (12.9) | ||||
Other assets | 24.3 | 23.2 | 1.1 | ||||
Non-current assets | |||||||
Lease assets | 561.8 | – | 561.8 | ||||
Intangible assets | 242.0 | 247.7 | (5.7) | ||||
Other assets | 178.2 | 175.5 | 2.7 | ||||
Total increase in assets | 497.0 | ||||||
Current liabilities | |||||||
Trade and other payables | 566.9 | 567.2 | (0.3) | ||||
Lease liabilities | 44.8 | – | 44.8 | ||||
Provisions | 41.7 | 42.4 | (0.7) | ||||
Other liabilities | 5.0 | 23.2 | (18.2) | ||||
Non-current liabilities | |||||||
Lease liabilities | 600.2 | – | 600.2 | ||||
Provisions | 86.6 | 78.2 | 8.4 | ||||
Deferred tax liabilities | 45.6 | 54.3 | (8.7) | ||||
Other liabilities | 45.9 | 140.4 | (94.5) | ||||
Shareholders’ equity | |||||||
Retained earnings | 817.2 | 851.2 | (34.0) | ||||
Total increase in liabilities and equity | 497.0 |
Quarter ended March 31 | |||||||
(In millions of Canadian dollars) |
2019
as reported $ |
2019
before IFRS 16 $ |
Increase (decrease) $ |
||||
Impact on income statement items | |||||||
Administrative and marketing expenses | 357.1 | 392.6 | (35.5) | ||||
Net interest expense | 17.2 | 9.1 | 8.1 | ||||
Depreciation of lease assets | 27.4 | – | 27.4 | ||||
Net income | 44.9 | 44.9 | – | ||||
Impact on non – IFRS financial measures(1) | |||||||
EBITDA | 132.2 | 96.7 | 35.5 | ||||
Adjusted EBITDA | 127.1 | 91.6 | 35.5 | ||||
Net debt/adjusted EBITDA – Continuing operations | 2.00 | 2.67 | (0.67) | ||||
(1) Non-IFRS measures are discussed in the Definitions section of Stantec’s 2018 Annual Report and Q1 19 Management’s Discussion and Analysis. Net debt/adjusted EBITDA was calculated using a proforma IFRS 16 adjustment for Q2 18 to Q4 18 adjusted EBITDA, calculated as 3.8% of net revenue from the respective quarter. |
Impact on Statement of Cash Flows – Continuing Operations | Quarter ended March 31 | ||||||
(In millions of Canadian dollars) |
2019
as reported $ |
2019
before IFRS 16 $ |
Increase
(decrease) $ |
||||
Cash flows used in operating activities | (88.5) | (114.1) | 25.6 | ||||
Cash paid to suppliers | (515.0) | (548.7) | 33.7 | ||||
Interest paid | (17.9) | (9.8) | (8.1) | ||||
Cash flows from investing activities | (104.2) | (99.4) | (4.8) | ||||
Proceeds from leasehold inducements | – | 4.8 | (4.8) | ||||
Cash flows from financing activities | 68.2 | 89.0 | (20.8) | ||||
Payments of lease obligations | (25.6) | – | (25.6) | ||||
Proceeds from leasehold inducements | 4.8 | – | 4.8 |
Reconciliation of Non-IFRS Financial Measures | |||||
Quarter Ended
March 31 As reported |
|||||
(In millions of Canadian dollars, except per share amounts) | 2019 | 2018 | |||
Net income from continuing operations | 44.9 | 36.6 | |||
Add back: | |||||
Income taxes | 13.6 | 13.6 | |||
Net interest expense | 17.2 | 5.3 | |||
Depreciation and amortization | 56.5 | 31.4 | |||
EBITDA from continuing operations | 132.2 | 86.9 | |||
Add back (deduct) pre-tax: | |||||
Unrealized (gain) loss on investments held for self-insured liabilities |
(5.1) | 2.6 | |||
Adjusted EBITDA from continuing operations | 127.1 | 89.5 | |||
Quarter Ended March 31 |
|||||
(In millions of Canadian dollars, except per share amounts) |
2019 | 2018 | |||
Net income from continuing operations | 44.9 | 36.6 | |||
Add back (deduct) after tax: | |||||
Amortization of intangible assets related to acquisitions(1) | 7.0 | 9.4 | |||
Unrealized (gain) loss on investments held for self-insured liabilities(2) |
(3.7) | 1.9 | |||
Transition tax(3) | 2.1 | – | |||
Adjusted net income from continuing operations | 50.3 | 47.9 | |||
Weighted average number of shares outstanding – basic | 111,805,946 | 114,064,729 | |||
Weighted average number of shares outstanding – diluted | 111,805,946 | 114,306,834 | |||
Adjusted earnings per share from continuing operations | |||||
Adjusted earnings per share – basic | 0.45 | 0.42 | |||
Adjusted earnings per share – diluted | 0.45 | 0.42 | |||
See the Definitions section of Stantec’s 2018 Annual Report and Q1 19 Management’s Discussion and Analysis for a discussion of non-IFRS measures used. Construction Services operations are presented as discontinued operations. This table has been updated to include only continuing operation results. |
|||||
(1) The add back of intangible amortization relates only to the amortization from intangible assets acquired through acquisitions and excludes the amortization of software purchased by Stantec. For the quarter ended March 31, 2019, this amount is net of tax of $2.7 (2018 – $3.5). |
|||||
(2) For the quarter ended March 31, 2019, this amount is net of tax of $1.4 (2018 – $0.7 recovery). |
|||||
(3) Refer to Income Taxes section of the Q1 19 Management’s Discussion and Analysis for further details. |
Contacts
Investor Contact
Cora Klein
Stantec Investor Relations
780-969-2018
cora.klein@stantec.com
Media Contact
Stephanie Smith
Stantec Media Relations
780-917-7230
stephanie.smith2@stantec.com
![](https://grassnews.net/wp-content/uploads/2019/03/Grassnews-600px.png)
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Innocan
Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center
![innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center](https://grassnews.net/wp-content/uploads/2024/07/61449-innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center.jpg)
HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.
The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.
Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.
“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”
Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html
Cannabis
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location
![](https://grassnews.net/wp-content/uploads/2024/07/verano-announces-the-opening-of-zen-leaf-fairless-hills-the-companys-newest-affiliated-dispensary-in-pennsylvania-in-prime-new-location.gif)
- Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
- As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
- Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity
CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.
The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.
“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”
Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.
About Verano
Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf™ and MÜV™ dispensary banners, including Cabbage Club™, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano™, (the) Essence™, MÜV™, Savvy™, BITS™, Encore™, and Avexia™. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.
Contacts:
Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com
Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.
###
1 Pennsylvania Department of Transportation
2 United States Census Bureau
Cannabis
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
![](https://grassnews.net/wp-content/uploads/2024/07/unlocking-new-horizons-in-health-tnr-the-niche-research-reveals-the-transformative-power-of-minor-cannabinoids.gif)
Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.
Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.
Global Minor Cannabinoids Market: Key Datapoints
Market Value in 2023 |
US$ 17.8 Bn |
Market Value Forecast by 2034 |
US$ 42.3 Bn |
Growth Rate
|
8.2% |
Historical Data
|
2016 – 2022 |
Base Year
|
2023 |
Forecast Data
|
2024 – 2034 |
Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.
The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.
The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.
The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.
Global Minor Cannabinoids Market: Key Takeaways of the Report
- Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
- Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
- In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.
Key Development:
- In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
- In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.
Browse Related Category Reports
Global Minor Cannabinoids Market:
- Aurora Europe GmbH
- BulKanna
- CBD. INC.
- Fresh Bros Hemp Company
- GCM Holdings, LLC (Global Cannabinoids)
- GenCanna.
- High Purity Natural Products.
- Laurelcrest
- Mile High Labs
- PBG Global
- Rhizo Sciences
- ZERO POINT EXTRACTION, LLC
- Other Industry Participants
Global Minor Cannabinoids Market
By Product Type
- Cannabigerol (CBG)
- Cannabichromene (CBC)
- Cannabinol (CBN)
- Cannabidivarin (CBDV)
- Tetrahydrocannabutol (THCB)
- Tetrahydrocannabivarin (THCV)
- Tetrahydrocannabiphorol (THCP)
- Others
By Application
- Pharmaceutical
- Pain Management
- Mental Health
- Sleep Disorders
- Anti-inflammatory
- Others
- Nutraceuticals
- Cosmetics and Personal Care
- Food and Beverages
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Consult with Our Expert:
Jay Reynolds
The Niche Research
Japan (Toll-Free): +81 663-386-8111
South Korea (Toll-Free): +82-808- 703-126
Saudi Arabia (Toll-Free): +966 800-850-1643
United Kingdom: +44 753-710-5080
United States: +1 302-232-5106
Email: askanexpert@thenicheresearch.com
Website: www.thenicheresearch.com
-
Cannabis2 weeks ago
IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis
-
Cannabis1 week ago
Blank Rome Bolsters Energy Industry Team in Houston and Pittsburgh with Leading Transactional Group
-
Cannabis2 weeks ago
Fractional Flow Reserve Market growing at a CAGR of 15.56% during the forecast period [2024-2030] – Exactitude Consultancy
-
Cannabis1 week ago
Manitoba Harvest Hemp Foods and Brightseed® Introduce New Coffee and Chocolate Flavors in Organic Bioactive Fiber Supplement for Gut Health
-
Cannabis4 days ago
Europe Medical Cannabis Oil Market Set to Reach Valuation of USD 2,395.83 Million by 2032 | Astute Analytica
-
Cannabis4 days ago
Global Agricultural Textiles Market Size To Worth USD 25.02 Billion By 2033 | CAGR of 4.70%
-
Cannabis1 day ago
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
-
Cannabis15 hours ago
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location